Get started
BPTH could be in for a bull market in 2025!One new low cap stock pick with my research described below, please do your own research aswell and remember these are risky moves - thus small allocation. I will be back with many crypto charts for next year as well, don't worry! Bio-Path Holdings (BPTH) Overview: Bio-Path Holdings, Inc. is a biotechnology company focused on developing nucleic acid cancer drugs using its proprietary DNAbilize antisense RNAi nanoparticle technology. This technology allows for the development of drugs that can be administered through intravenous transfusion, targeting specific genes associated with cancer. Last week, Bio-Path Holdings announced preclinical results for their drug candidate BP1001-A. The study demonstrated that BP1001-A enhances insulin sensitivity, suggesting its potential as a treatment for obesity in patients with Type 2 diabetes. In 2025, Bio-Path Holdings plans to initiate a first-in-human Phase 1 clinical trial for BP1001-A, focusing on validating its safety, measuring pharmacokinetics, and establishing dosing for potential pivotal trials. This trial is aimed at further exploring BP1001-A's potential as a treatment for obesity and related metabolic diseases in patients with Type 2 diabetes. A successful trial would likely lead to a significant increase in Bio-Path Holdings' stock price. The news of positive clinical results would be seen as a validation of the drug's potential, attracting more investor interest and possibly leading to partnerships or buyouts from larger pharmaceutical companies. SPECULATION: Estimating the yearly revenue potential and a fair valuation for Bio-Path Holdings (BPTH) based on BP1001-A's market entry involves several speculative assumptions, as we lack specific data on market penetration, pricing, competition, and long-term efficacy. Here's a theoretical breakdown: Revenue Potential: Market Size and Share: Obesity and Type 2 Diabetes Market: The global market for treatments of obesity and Type 2 diabetes is substantial. For context, the global diabetes market alone was valued at approximately $51.1 billion in 2022, expected to reach $81.6 billion by 2030, growing at a CAGR of around 6.5% (). However, BP1001-A would be competing in a segment of this market focused on novel treatments or those with a unique mechanism like insulin sensitivity enhancement. Assumed Market Share: Assuming BP1001-A captures a niche segment, let's speculate it achieves a 1% to 5% market share due to its novel mode of action and targeting a specific subset of Type 2 diabetes patients with obesity. Pricing and Usage: Drug Pricing: New diabetes drugs, especially those with innovative mechanisms, can be priced high. For instance, if we assume a yearly cost per patient of $10,000 (considering the high cost of biologics and similar therapies), Patient Population: If we estimate that 1% of the diabetic population globally (approximately 537 million adults in 2021 according to IDF) could benefit from this drug, that's about 5.37 million patients. At 5% market share, this would mean 268,500 patients. Revenue Calculation: Annual Revenue: If 268,500 patients use BP1001-A at $10,000 per year, the potential annual revenue would be approximately $2.685 billion. For a 1% market share (53,700 patients), it would be around $537 million. Valuation: DCF Approach: A Discounted Cash Flow (DCF) analysis would be the traditional method to value BPTH if BP1001-A were to generate such revenues. Here's a simplified speculative approach: Cash Flow: Assuming 50% of revenue translates into gross profit (considering R&D, marketing, and other costs), a 1% market share would yield $268.5 million in gross profit, and 5% would yield $1.3425 billion. Discount Rate: Biotech companies often have high discount rates due to risk. Let's assume a 15% discount rate for this speculative valuation. Growth & Terminal Value: Assume growth stabilizes after initial high growth years, with a terminal growth rate of 2% post-patent exclusivity period (which might be around 20 years from patent to market). Valuation Calculation: With a 1% market share scenario: Present Value of Cash Flows for first 10 years (assuming rapid growth then stabilization): $268.5M * Annuity Factor at 15% = $1.4 billion (very roughly). Terminal Value (Gordon Growth Model) = $268.5M * (1+0.02)/(0.15-0.02) = $2.14 billion. Total Equity Value = PV of cash flows + Terminal Value = $3.54 billion. With a 5% market share scenario: Present Value of Cash Flows for first 10 years: $1.3425B * Annuity Factor at 15% = $7 billion (again, very roughly). Terminal Value = $1.3425B * (1+0.02)/(0.15-0.02) = $10.7 billion. Total Equity Value = $17.7 billion. Market Multiples: If we use industry multiples (PE ratios for biotech can be very high, especially for novel treatments), with a PE ratio of 20-30 for a company with significant growth potential, the valuation based on earnings from BP1001-A alone would range from: 1% Market Share: $5.37 billion (20 * $268.5M) to $8.055 billion (30 * $268.5M). 5% Market Share: $26.85 billion (20 * $1.3425B) to $40.275 billion (30 * $1.3425B). Fair Valuation: Given these speculative numbers, a fair valuation for BPTH based solely on BP1001-A's potential would be somewhere in the middle of these ranges, adjusted for the company's current financials, other pipeline drugs, and market conditions. Considering the above, a conservative estimate might place BPTH's valuation in the range of $3 billion to $10 billion, depending on market penetration optimism, with the understanding that this is highly speculative and subject to countless variables including regulatory approval, actual market acceptance, and competitive landscape. CONCLUSION & TA: This simply means, IF(!) this drug is succesfull the market cap of this company would significantly rise. Currently we're sitting at a 5.43 million market cap (at close, so lower now), thus its a 100 to 1000x potential or it drops to zero. Last note, price needs to stay above $1 to stay compliant with Nasdaq rules or else there could be an inverse stock split 2 to 1 for example or they face delisting by the end of Q3 2025. I'm not too worried because this is the same as SEALSQ faced before it 10x'd in the last few weeks. TA wise: we're retesting previous resistance and the bull market support band. Chart has been down only for years, capitulation after capitulation thus chance of a rebound should be there. I grabbed a small allocation to sit out for 2025, if the clinical trials are successful, we'll in for a big bull market. If not succesfull, we'll likely lose our money. A very decent risk / reward ratio of you invest an amount you can afford to lose and not more than 5% of your portfolio. This is one of my low cap stock picks, next to LAES (10x since entry) and MOBX (entry last week, flat pa for now). I will be scouting for more but for now, happy holidays!
NASDAQ:BPTHLong
by cryptobullethbtcxlm
$ZETA will continue to climb up > $30 - Ignore FUD, accumulate like the whales 🐋 - Zeta Global Holdings Corp. (NYSE: ZETA) reported robust financial performance in the third quarter of 2024, with revenue reaching $268 million—a 42% year-over-year increase. STOCK TARGET ADVISOR - This growth underscores the company's strong market position and effective strategic initiatives. - Analysts have responded positively, with Needham & Company LLC reaffirming a "buy" rating and setting a price target of $43.00, suggesting a potential upside of approximately 99.81% from the current share price.
NYSE:ZETALong
by bigbull037
Micron Technology ($MU): Breaking Resistance or Building Moment "Undervalued tech stocks are like treasure maps—the trick is knowing where the 'X' marks the breakout. Let’s see where NASDAQ:MU might lead us." Valuation Insight: "Micron Technology ( NASDAQ:MU ) is trading at $87.50, with valuation metrics that scream potential: P/E Ratio: 10.5—well below industry averages. P/B Ratio: 1.7—value investors, take note. EV/Revenue Ratio: 3.5—a discount on future growth." Key Resistance Levels to Watch: $97.18 – The First Test 🎯 "This level marks the first hurdle for $MU. A breakout above could indicate momentum building toward a bullish trend." $118.54 – The Big Break ⚡ "Crossing this level would confirm renewed bullish sentiment. Look for strong volume as a signal for sustained movement." $181.66 – The Bullish Peak 🏔️ "While distant, this historical high serves as a long-term target for investors betting on sustained industry growth." Growth Catalysts: AI and 5G Demand: DRAM and NAND memory are critical for emerging technologies. Institutional Activity: Dark pool orders and market-on-close volume indicate increased interest from big players. Risks to Watch: Cyclical Nature: Overproduction or slowing demand could impact prices. Macroeconomic Headwinds: Higher interest rates might dampen near-term spending in tech. Conclusion: " NASDAQ:MU is undervalued and approaching critical levels—$97.18, $118.54, and $181.66—that could define its path forward. Keep these zones on your radar and watch for volume to validate potential moves."
NASDAQ:MULong
by DCAChampion
Maximize Gains with AAPL: Key Levels and Insights for Next Week - Recent Performance: Apple Inc. (AAPL) has shown remarkable resilience in the technology sector, reaching an all-time high of $255 recently. This upward movement underscores the strong investor confidence, driven largely by robust earnings and a promising outlook despite mixed broader market sentiments. - Key Insights: AAPL continues to navigate critical resistance levels effectively. The key price resistance currently stands at $255, and should this level be exceeded, analysts believe the price could target $260. The upcoming iPhone 16 launch is poised to further bolster investor confidence and foster a positive sentiment towards the stock. - Expert Analysis: Market experts maintain a bullish outlook on AAPL, highlighting the importance of maintaining above the $246 support level. If AAPL can hold this critical support, the stock may set itself up for a rally as it targets higher resistance levels. The prevailing sentiment within the tech sector suggests that AAPL, alongside other front-runners like Nvidia, may lead potential breakouts in the near term. - Price Targets: - Next week targets: T1 = $260, T2 = $265 - Stop levels: S1 = $246, S2 = $243 - News Impact: The high anticipation surrounding the launch of the iPhone 16, with expectations of over 90 million units sold, adds a layer of excitement to AAPL’s growth prospects. Additionally, ongoing regulatory scrutiny in the EU could influence market sentiments, making it essential for investors to stay informed about impending developments that may affect stock performance. In conclusion, AAPL is well-positioned for growth, and traders should closely monitor the outlined price targets and support levels as the company gears up for significant product launches and navigates the evolving market landscape.
NASDAQ:AAPLLong
by CrowdWisdomTrading
COST with Strong Resistance Divergence **Costco (COST)** has not yet reported its results for the quarter ending in November 2024. The results are expected to be released on **December 12**. This warehouse club operator is expected to post quarterly earnings of **$3.79 per share** in its upcoming report, which represents a year-over-year change of **+8.9%**. The consensus EPS estimate for the quarter has been revised **0.1% higher** over the last 30 days to the current level. Costco's revenues are expected to be **$62.37 billion**, up **7.9%** from the year-ago quarter. For now its expected to have a dropp down twoard the lower channel supported by strong negaptive resistance in addtional it seems Options Market makers are looking to burn 955 and 1000 Call 29 Nov Contracts
NASDAQ:COSTShort
by Nashwan
Nvidia poised for potential bullish breakout next week - Recent Performance: Nvidia has exhibited notable volatility in the market, managing to score over 3% gains within the past week. The stock has remained a central focus in the tech sector, demonstrating resilience despite broader market fluctuations. Analysts are now eyeing this volatility, viewing it as a precursor to further movements, especially as the stock approaches critical resistance levels. - Key Insights: Investors should consider Nvidia as a strong buy opportunity, particularly due to its ability to hold above crucial price thresholds. A breakout beyond the resistance range of $136 to $137 could catalyze a more significant upward trend. The continued strength in the AI sector serves as a major growth driver, underscoring Nvidia's potential in a rapidly evolving technology landscape. - Expert Analysis: The market sentiment surrounding Nvidia is overwhelmingly optimistic. Analysts agree on the high probability of a breakout, which if achieved, would mark a bullish shift for the stock. They stress that maintaining prices above key support levels is essential for sustaining positive momentum, as Nvidia continues to lead in the AI space amid rising market demand. - Price Targets: Based on current market analysis, the price targets for next week are as follows: - Next week targets: T1 = 138, T2 = 144 - Stop levels: S1 = 132, S2 = 125 - News Impact: Nvidia has recently gained attention due to its strategic partnerships aimed at enhancing AI capabilities, including significant collaborations in India. The company anticipates remarkable revenue growth driven by the demand for its AI-based products, forecasting a 79% increase. The introduction of the new Blackwell AI processor has further excited analysts and investors alike, reinforcing Nvidia's strong market position. Overall, solid performance metrics, expert optimism, significant support and resistance levels, and important partnerships collectively suggest Nvidia is well-positioned for growth in the upcoming week.
NASDAQ:NVDALong
by CrowdWisdomTrading
Aiming for Bullish Momentum: PLTR Set for Next WeekRecent Performance: Palantir Technologies (PLTR) has seen a notable rise in its stock price following its inclusion in the NASDAQ 100. The market has reacted positively, reflecting strong investor interest underpinned by solid earnings driven by government contracts and advancements in AI. Analysts predict potential hurdles at the resistance levels of $82 to $85, while a key support level around $75 serves as a safety net against drastic declines. - Key Insights: Investors should pay attention to the potential bullish momentum as PLTR approaches critical resistance levels. The rapid growth in government contracts coupled with strategic partnerships positions the company well for continued expansion, especially in the defense sector. However, the mixed sentiments on valuation sustainability suggest a need for cautious trading and monitoring market movements closely. - Expert Analysis: Market sentiment on PLTR is generally optimistic despite the polarized views from analysts. While some voices express concerns regarding valuation, the prevailing sentiment leans towards confidence in Palantir's AI capabilities and government initiatives. This mixed but predominantly bullish sentiment could drive price movements in the upcoming week. - Price Targets: Based on professional traders' insights: Next week targets: T1 = 84, T2 = 87. Stop levels: S1 = 75, S2 = 73. This positioning allows for a safeguarded long strategy while targeting upside potential in line with recent market performance. - News Impact: Recent strategic moves, such as the partnership with Booz Allen Hamilton, highlight Palantir's ongoing efforts to secure more government contracts. The impressive 40% year-over-year increase in US government revenue further underscores this trend, alongside the FedRAMP High authorization for federal cloud services. These developments not only bolster Palantir's credibility but also enhance growth prospects, positively influencing market sentiment.
NASDAQ:PLTRLong
by CrowdWisdomTrading
Could Palantir become the new Nvidia?Could Palantir become the new Nvidia? In the year 2023, I was one of the few who predicted Nvidia's great success, and today I will talk about another company that could follow in its footsteps: Palantir. Artificial intelligence will become increasingly important for businesses as it moves from the experimental stage to strategic adoption. This will help solve specific problems and promote efficiency, innovation, and sustainable growth within companies. Alongside industry giants such as Alphabet, Microsoft, Amazon and Meta, this company could represent a real revolution in the way data is managed and processed in the AI ecosystem, Offering solutions that redefine the standards of enterprise software and advanced analytics. Although Nvidia is at the top of the AI hardware market, Palantir's future will depend on its ability to make their software and data analytics solutions indispensable, in a market where names like Snowflake and Databricks already stand out. In the current technology landscape, Palantir Technologies Inc (NASDAQ:PLTR) stands out as one of the most interesting companies. Over the past two years it has implemented major changes in its business model and consolidated its position as a leader in the use of artificial intelligence for data analysis. The launch of the Artificial Intelligence Platform (AIP) has enabled Palantir to integrate advanced language models with complex data from the corporate world, providing an invaluable solution for numerous clients in both the public and private sectors. Palantir's strength lies in its ability to combine business data with artificial intelligence, turning a chaotic mass of information into clear and concrete operational decisions. It is a real revolution in the way companies manage and use their data. With global spending estimated at more than $1 trillion over the next three years, artificial intelligence is becoming increasingly important. There are many opportunities for companies to establish themselves as strategic partners in the management and use of data. While Nvidia is a leader in hardware, Palantir could become a key player in software and have significant growth margins by 2025. Being a leading artificial intelligence company is not only about innovation and technological development, but also about financial success in the market. Wall Street valuation and company fundamentals are equally important to reach the top of the industry. In 2025, after the stock moves from the New York Stock Exchange (NYSE) to Nasdaq next Dec. 23, Palantir is expected to continue to grow and gain value. In the third quarter of 2024, the company saw 30 percent year-over-year revenue growth and generated adjusted free cash flow of $434.5 million. Its financial results show that Palantir is moving toward more growth, as evidenced by its earnings forecast for the next quarter ($0.11 per share), which is up 37.5 percent from the same period last year. In addition, revenue is continuing to develop positively with a projected 28.3 percent growth for this quarter. Palantir has made multimillion-dollar deals with various partners, including a five-year contract worth nearly $100 million to improve the U.S. military's artificial intelligence and machine learning capabilities. Unlike other software companies, Palantir's strength lies in its ability to provide proprietary solutions that optimize the use of AI and increase the operational efficiency of its customers. This unique position has led some experts to predict the stock will rise as much as 111 percent by 2025. Right now, the stock is expensive, but if there is a technical price correction around $50, I will buy the stock with a goal of reaching $100. If you would like to be notified whenever I post a new article, just click on “FOLLOW” at the top. Also, if you would like to elaborate on a particular topic or need some advice, please comment below the article and I will be happy to help you.
NASDAQ:PLTRLong
by Antonio_Ferlito
Technical Analysis of Johnson & Johnson Stock (JNJ)This chart for JNJ illustrates a technical setup within a descending channel. Key Fibonacci retracement levels (38.2%, 50%, and 61.8%) are highlighted, indicating potential zones of support and resistance. The analysis suggests a three-part buying strategy: an initial purchase at the current market price (CMP) near a double-bottom structure, a second purchase around the $138–$136 range (61.8% Fibonacci level), and a third at the $133–$135 channel bottom. A stop loss is defined at $130 on a closing basis to manage downside risk, emphasizing disciplined trading within the defined channel boundaries.
NYSE:JNJLong
by jayshafiq2
NVDA Bullish Trade Setup: Key Levels to Watch Monday!**📈Entry**: **$134.97** – Price is breaking out above key resistance, confirming bullish momentum. 🚀 **Stop Loss**: **$130.95** – Protect against downside risk below support. ✋ 🎯 **Targets**: - **T1**: $140.34 – First resistance level and profit-taking zone. 🛑 - **T2**: $144.64 – Extended upside target for greater profits. 💰 **Key Details**: 📊 Breakout above the descending trendline confirms bullish pressure. 📈 Entry near $134.97 offers a favorable risk-reward ratio for long trades. **📌 Strategy**: - 🟢 Enter long at $134.97. - 🔒 SL below $130.95. - ✅ Take profits at $140.34 (T1) & $144.64 (T2). **Why This Chart is Important**: ⚠️ NVDA is showing clear bullish signals, offering an ideal setup for breakout traders. **Conclusion**: Breakout at $134.97 with targets at $140.34 and $144.64 confirms bullish momentum, making this a strategic long trade opportunity. 📈🔥 #Trading #NVDA #StockMarket #BullishSetup #RiskReward #StockAnalysis #ProfittoPath
NASDAQ:NVDALong
by Xeeshan79
Puts/Short setup on DRI (Darden Restaurants)NYSE:DRI gapped Up on Dec 19th. Fibonacci technical analysis: Now finding Resistance at Fib level –61.8% (188.82) on Upward Fib and Double Top formed. Price likely to retrace lower to retest the gap. My Downward Fib shows retracement levels 38.2 % at 171, 61.8% at 166.5, and 78.6% at 164. PUTS on NYSE:DRI with Target 1 at 178, Target 2 at 171, and Target 3 at 166.5 Stop Loss slightly above the –78.6% extension Fib level (199.25)
NYSE:DRIShort
by rose_excellence
4